Roles of aldosterone in vascular calcification: An update

Jingwei Gao, Kun Zhang, Jie Chen, Mong-Heng Wang, Jingfeng Wang, Pinming Liu, Hui Huang

Research output: Contribution to journalReview article

12 Scopus citations

Abstract

Both clinical and experimental studies have demonstrated that vascular calcification (VC) is a common pathology shared in many chronic diseases such as chronic kidney disease (CKD) and diabetes. It's an independent risk factor for cardiovascular events. Since the pathogenesis of VC is complicated, current therapies have limited effects on the regression of VC. Therefore, it is urgent to investigate the potential mechanisms and find new targets for the treatment of VC. Aldosterone (Aldo), a mineralocorticoid hormone, is the metabolite of renin-angiotensin-aldosterone system (RAAS) activation, which can exert genomic and non-genomic effects on the cardiovascular system. Recent data suggests that Aldo can promote VC. Here, we summarized the roles of Aldo in the process of VC and a series of findings indicated that Aldo could act as a potentially therapeutic target for treating VC.

Original languageEnglish (US)
Pages (from-to)186-193
Number of pages8
JournalEuropean Journal of Pharmacology
Volume786
DOIs
Publication statusPublished - Jan 1 2016

    Fingerprint

Keywords

  • Aldosterone
  • Genomic mechanisms
  • Non-genomic mechanisms
  • Vascular calcification
  • Vascular smooth muscle cells

ASJC Scopus subject areas

  • Pharmacology

Cite this